Soren Acquisition Corp. Prices $220 Million Initial Public Offering

Soren Acquisition Corp. Launches $220 Million IPO with a Focus on Healthcare

Miami, FL – January 6, 2026 – Soren Acquisition Corp. has announced the pricing of its initial public offering, aiming to raise $220 million. The special purpose acquisition company (SPAC) is set to offer 22 million units at $10.00 per unit, with trading on the Nasdaq Capital Market slated to commence on January 7, 2026, under the ticker symbol “SORNU.”

Each unit comprises one Class A ordinary share and one-third of a redeemable warrant. These warrants, exercisable at $11.50 per share, will trade separately under the ticker “SORNW” once the units begin to separate. The offering is anticipated to close on January 8, 2026, with underwriters holding a 45-day option to acquire an additional 3.3 million units to cover any overallotments.

This IPO marks a significant step for Soren Acquisition Corp., a blank check company strategically targeting business combinations within the dynamic healthcare sector. The company’s management team, spearheaded by Chief Executive Officer Arghavan Di Rezze and Chief Financial Officer Jamie Weber, brings a wealth of experience to the table. They are supported by a robust board of directors, including Marc Mazur, Charles N. Khan III, and Spencer Gerrol, alongside advisors Peter Ondishin and Nicholas Shekerdemian. BTIG, LLC is serving as the sole book-running manager for this offering.

The healthcare industry presents a fertile ground for SPACs, driven by innovation in biotechnology, pharmaceuticals, and medical technology. Companies in this space often require substantial capital for research and development, clinical trials, and market expansion. Soren Acquisition Corp.’s focused mandate suggests a deliberate strategy to identify and merge with a target that can leverage public market access to accelerate growth and innovation.

The structure of the offering, with units comprising shares and warrants, is a common feature of SPAC IPOs. Warrants can be attractive to investors as they offer potential upside if the company’s stock price appreciates beyond the exercise price. However, they also represent a potential source of future dilution for existing shareholders. The $11.50 exercise price for the warrants indicates the company’s expectation that its target business combination will result in a valuation significantly exceeding this level.

The decision to focus on healthcare is particularly noteworthy. This sector has seen a surge in SPAC activity, fueled by the increasing demand for advanced healthcare solutions and the potential for disruptive technologies. Navigating this landscape requires deep industry expertise, a robust network, and a keen understanding of regulatory frameworks. Soren’s management team appears poised to tackle these challenges, aiming to identify a target with strong fundamentals and a clear path to value creation.

The total gross proceeds of $220 million position Soren Acquisition Corp. with considerable dry powder to pursue its acquisition strategy. The success of this IPO will be closely watched as an indicator of investor appetite for SPACs, particularly those with a specific industry focus like healthcare. The upcoming business combination will be critical in demonstrating the value proposition of this SPAC and its ability to generate returns for its shareholders.

This press release contains forward-looking statements regarding the offering and the search for a business combination. Actual results may differ materially due to various risks and uncertainties.